Filters

Term Search
You can select from the dropdown list OR enter your own terms to refine the search.

Last Updated: 01/07/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 491 publications

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Peri-transplant conundrums: optimizing maintenance therapy using MRD-directed approaches.

Journal: Hematology. American Society of Hematology. Education Program
Published: December 05, 2025

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

Sphingosine-1-phosphate receptor modulators resensitize FLT3-ITD acute myeloid leukemia cells with NRAS mutations to FLT3 inhibitors.

Journal: bioRxiv : the preprint server for biology
Published: December 04, 2025

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors.

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors.

Journal: Journal of visualized experiments : JoVE
Published: November 03, 2025

Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML.

Post-HCT gilteritinib outweighs conditioning in NPM1m FLT3-ITD AML.

Journal: Blood advances
Published: October 16, 2025

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.

Journal: Leukemia & lymphoma
Published: October 03, 2025

FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

FLT3: A 35-Year Voyage from Discovery to the Next Generation of Targeted Therapy in AML.

Journal: Cancers
Published: September 25, 2025

Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors.

Acute myeloid leukemia drug resistance: targetable nodes and the clinical trajectory of small-molecule inhibitors.

Journal: Frontiers in pharmacology
Published: August 31, 2025

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Outcomes of relapsed or refractory acute myeloid leukemia after menin inhibition failure.

Journal: Blood advances
Published: August 22, 2025

Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics.

Rational design of next-generation FLT3 inhibitors in acute myeloid leukemia: From laboratory to clinics.

Journal: European journal of medicinal chemistry
Published: August 19, 2025

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Antipsychotic Chlorpromazine Suppresses STAT5 Signaling, Overcomes Resistance Mediated by the Gatekeeper Mutation FLT3-ITD/F691L, and Synergizes with Quizartinib in FLT3-ITD-Positive Cells.

Journal: Current issues in molecular biology
Published: August 16, 2025

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

Journal: American journal of hematology
Published: August 08, 2025

Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.

Updates on Therapy Options in Fit and Unfit Patients with Newly Diagnosed AML.

Journal: Current treatment options in oncology
Published: July 30, 2025
Showing 1-12 of 491

Last Updated: 01/07/2026